Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy

Basit Öğe Kaydı
dc.contributor.authorYavaş, Güler
dc.contributor.authorÇelik, Esin
dc.contributor.authorYavaş, Çağdaş
dc.contributor.authorElsürer, Çağdaş
dc.contributor.authorAfşar, Rengin Elsürer
dc.date.accessioned2020-03-26T19:42:41Z
dc.date.available2020-03-26T19:42:41Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAim: We aimed to evaluate impact of spironolactone (S) on cardiovascular toxicity of concomitant use of radiotherapy (RT) and trastuzumab (T). Background: S, an aldosterone receptor antagonist, is known to ameliorate the cardiac damage. S ameliorates anthracycline-induced cardiotoxicity, there is no data regarding to effect of S on both T and radiation-induced cardiotoxicity. Materials/Methods: Eighty rats were divided into eight groups: group (G) 1 was defined as control group. G2, G3 and G4 were RT, S and T groups respectively. G5, G6, G7 and G8 were RT + T, T + S, RT + S and RT + T + S groups respectively. Rats were sacrificed at 6th hour; 21st and 100th days after RT. Heart and thoracic aorta samples were taken for microscopical examination. Results: Cardiac inflammation and fibrosis scores and; TGF-8 expression were not significantly different within study groups at 6th hour and 21st days of RT. By 100th days of RT fibrosis scores and TGF-expression in cardiac samples were significantly different between study groups (p values were 0.004 and 0.002 respectively). Pair-wise comparisons revealed that both cardiac fibrosis scores and TGF-8 expression levels were higher in G5 when compared to G8 (p values were 0.046 and 0.028 respectively). Moreover the TGF-8 expression was higher in G5 when compared to G2 (p =0.046). We could not demonstrate any significant differences with respect to inflammation, fibrosis and TGF-8 expression in thoracic aorta samples between study groups. Conclusions: Although S had a protective effect on cardiac tissue it had no protective effect on thoracic aorta when administered with RT + T. (C) 2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.en_US
dc.description.sponsorshipSelcuk UniversitySelcuk Universityen_US
dc.description.sponsorshipThis work was supported by Selcuk University. There is no role of study sponsors in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript and in the decision to submit the manuscript for publication.en_US
dc.identifier.doi10.1016/j.rpor.2017.01.004en_US
dc.identifier.endpage302en_US
dc.identifier.issn1507-1367en_US
dc.identifier.issn2083-4640en_US
dc.identifier.issue4en_US
dc.identifier.pmid28507459en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage295en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.rpor.2017.01.004
dc.identifier.urihttps://hdl.handle.net/20.500.12395/35491
dc.identifier.volume22en_US
dc.identifier.wosWOS:000408486500005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofREPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAldosteroneen_US
dc.subjectCardiovascular toxicityen_US
dc.subjectRadiotherapyen_US
dc.subjectSpironolactoneen_US
dc.subjectTrastuzumaben_US
dc.titleSpironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu